Main Industry
Biotechnology
Main Product/Service
1. Trastuzumab Biosimilar
2. CDMO Services
3. CRM197 Carrier Protein
4. COVID-19 Antigen Rapid Test
2. CDMO Services
3. CRM197 Carrier Protein
4. COVID-19 Antigen Rapid Test
Founded Year
2012
Unified Business No.
54150737
Status
Active
Number of Employees
40
Total Paid-in
Capital
3,068,711,740 (NT$)
Location of Company
Taiwan
, New Taipei City
Exit Status
OTC listing(2019)
Information such as company name, company status, responsible person, year of establishment, paid-in capital, and registered address is sourced from the Commercial and Industrial Registration Office of the Ministry of Economic Affairs; listing status includes emerging stock, M&A, and IPO; overseas development is provided by the startup itself.
Notice: This data is compiled from public sources for reference only. We have no direct affiliation with the company and are not their contact person.
Exclusive content for members
Members-only content. Please log in to access.
About the Company
EirGenix Inc., health is important for all people. Under this belief, EirGenix established two business units to achieve the goal. One is contract development and manufacturing operation unit where EirGenix helps clients to manufacture their biologics; the other is the product development operation unit where they hope to fully apply theirteam's experience and knowledge on biologics from biosimilars, biobetters to new drugs. EirGenix's goal is that every patient can afford high-quality biopharmaceutical drugs.
